Cetrorelix regulatory status
Current status of Cetrorelix in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Cetrorelix?
Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 23, 2026
- FDA and compounding
- FDA approved prescription drug (Cetrotide, approved August 11, 2000) to inhibit premature LH surges in women undergoing controlled ovarian stimulation. Commercially available as a 0.25 mg kit, so it is not eligible for routine compounding and is not on any 503A bulks list. Not a research chemical.
- WADA
- Not WADA prohibited
- Access path
- Prescription from a fertility specialist as part of an IVF or egg freezing protocol, filled at a specialty or fertility pharmacy.
- Not available through compounding pharmacies or telehealth peptide clinics.
Full Cetrorelix page: evidence, dosing in the literature, and sources
How has the status of Cetrorelix changed over time?
No dated regulatory event has been recorded for Cetrorelix. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Cetrorelix and the source of each dated event.